Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 265

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

Statins and hepatotoxicity: Focus on patients with fatty liver†

Open access
Chalasani, Naga·2005·Hepatology

Abstract

Statins are among the most widely prescribed medications in the western world.1 Their benefit in the primary and secondary prevention of cardiovascular disease is unequivocal. The results from clinical trials have shown that statins decrease the mortality from coronary artery disease and decrease the incidence of myocardial infarction, revascularization procedures, stroke and peripheral vascular disease.2 Currently, six statins are available for clinical use including lovastatin which is available in a generic form in the United States. These medications are widely prescribed and more than 10 million prescriptions were written in the United States in the year 2003 alone3 (Table 1). Numerous clinical trials and extensive clinical experience have established that currently available statins have an excellent safety profile. Although clinically significant liver injury is extremely rare from statins, asymptomatic elevations in liver enzymes are common in patients who are placed on statins. Because of this phenomenon and due to the information contained within the package inserts, potential hepatotoxicity from statins has become a source of concern for physicians who prescribe them. In clinical practice, gastroenterologists and hepatologists are often asked to see patients who developed liver enzyme elevations after prescribing statins and also about the safety of prescribing statins in hyperlipidemic individuals with asymptomatic liver enzyme elevations. This article discusses various aspects of statin hepatotoxicity including the safety of statins in patients with nonalcoholic fatty liver disease (NAFLD) and the merits of current product labeling (Table 2). The issue of using statins in patients with known or suspected fatty liver disease is particularly relevant as statins are now available without a prescription in some parts of the world (United Kingdom) and thus a large number of individuals with undiagnosed fatty liver disease may consume statins without their knowledge. ALT, Alanine Aminotransferase; ULN, upper limit of normal; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis. Initial toxicology studies in animals suggested that statins may cause significant liver problems. Although the usual doses of lovastatin did not cause significant liver injury, when given in very high doses they caused hepatocellular necrosis in rabbits.4 Similarly, high doses of simvastatin caused hepatocellular necrosis in guinea pigs.5 The liver injury in these animals could be prevented or reversed with supplementing animals with mevalonate suggesting that depletion of mevalonate or its downstream metabolite might be responsible for liver injury.4, 5 However, it does not appear that statins cause hepatocellular necrosis in a predictable fashion in humans. The most common clinical hepatic manifestation of statins is asymptomatic elevation in aminotransferases and this appears to be a class effect of statins.2, 6-8 The clinical trials that evaluated the efficacy of statins have arbitrarily but consistently used persistent and significant elevation in alanine aminotransferase levels (>3 times upper limit of normal [ULN] on two or more measurements) as a safety end point. The incidence of this abnormality with different statins is less than 3% and there is a minor dose-related increase in its incidence2, 7 (Table 3). Very rarely, after initiating statins, the liver enzymes can rise to significantly higher levels with no evidence of liver dysfunction. For example, in the prospective pravastatin pooling project (PPP project), 0.5% of the patients who received 40 mg of pravastatin had ALT greater than 5 times ULN and 0.2% had ALT greater than 9 times ULN.9 In general, the incidence of liver enzyme elevations in the statin treated patients has not been consistently different than in the placebo-treated patients.9, 10 In a recent meta-analysis that consisted of 49,275 patients who participated in 13 large, placebo-controlled trials of statins, therapy with statins at low-to-moderate doses was not associated with a significant increase in liver enzyme elevations compared to placebo (OR 1.26, 95% CI 0.99-1.62).10 This comparable incidence of liver enzyme elevation between statin and placebo-treated patients raises the possibility that hyperlipidemic patients may have spontaneous fluctuations in transaminases whether or not they receive statins.9-12 In patients who exhibit elevated aminotransferases, the liver enzymes decrease upon stopping or reducing the dose.6 However, the natural history of elevated aminotransferases if the statins are continued at the same doses is not well known. There is a suggestion that such patients may exhibit "adaptation" and their aminotransferases remain stable or trend downwards even when statins are continued.6 Although several reports of significant liver injury associated with statins have appeared in the literature, it appears to be very rare.8, 13-16 Statins do not appear to

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hep.20671

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 43 references

Research works printed but not linked: 4

  1. Kemmer, 2001, High prevalence of NASH among Mexican American females with type II diabetes mellitus, Gastroenterology, 120, A117, 10.1016/S0016-5085(01)80576-X · doi:10.1016/s0016-5085(01)80576-x
  2. Burdick, 2004, Insulin related endothelial dysfunction in patients with nonalcoholic fatty liver disease (NAFLD), HEPATOLOGY, 40, 589A
  3. Lersch, 2004, Treatment of HCC with pravastatin, octreotide, or gemcitabine‐critical evaluation, Hepatogastroenterology, 51, 1099
  4. Shek, 2001, Statin‐fibrate combination therapy, Ann Pharmacother, 35, 908, 10.1345/aph.10315 · doi:10.1345/aph.10315 · Paper page

Cited by

See all 265

Metadata

Authors
Chalasani, N.
Venue
Hepatology
Published
2005-04
Volume
41
Issue
4
Pages
690-695
ISSN
0270-9139 (ISSN-L)
OpenAlex
W2089003251
Cited by
265
References
43
FWCI
16.39
Type
journal article
Language
en
Open access
bronze
Licence
doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 3805 d)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Statins and hepatotoxicity: Focus on patients with fatty liver†. https://app.cochat.ai/papers/10.1002/hep.20671
The paper
Chalasani, N. (2005). Statins and hepatotoxicity: Focus on patients with fatty liver†. Hepatology. https://doi.org/10.1002/hep.20671

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.